In a patient with tuberculous meningitis who has developed cerebral infarcts, should treatment be aspirin (antiplatelet) rather than therapeutic enoxaparin (anticoagulation)?

Aspirin vs Enoxaparin in Tuberculous Meningitis with Infarcts

In patients with tuberculous meningitis who develop cerebral infarcts, aspirin (antiplatelet therapy) should be used rather than therapeutic enoxaparin (anticoagulation). 1, 2

Rationale for Aspirin Over Anticoagulation

Anticoagulation is not recommended for acute ischemic stroke in general, and this principle extends to TBM-related infarcts. The mechanism of stroke in TBM is primarily inflammatory arteritis affecting the basal ganglia vessels (the "tubercular zone") rather than cardioembolic or large-vessel atherothrombotic disease. 3 Therapeutic anticoagulation with agents like enoxaparin carries substantial bleeding risk without proven benefit in this inflammatory vasculopathy. 4

Evidence Supporting Aspirin in TBM

• Aspirin significantly reduces the risk of new infarctions in TBM patients (RR 0.52,95% CI 0.29-0.92; moderate-quality evidence from meta-analysis of 4 trials including 546 patients). 5

• Aspirin combined with corticosteroids may reduce mortality in TBM, with one prospective registry study showing a trend toward survival benefit (HR 1.55,95% CI 0.96-26.49; P=0.07). 6

• The largest randomized trial (120 participants) demonstrated dose-dependent benefits: In microbiologically confirmed TBM, aspirin reduced the primary outcome of new infarction or death by day 60 from 34.4% (placebo) to 14.8% (aspirin 81 mg) and 10.7% (aspirin 1000 mg), p=0.06. 7

• Aspirin's mechanism in TBM is multifactorial: It provides anti-thrombotic effects, anti-inflammatory properties, inhibits thromboxane A2, and upregulates pro-resolving protectins in cerebrospinal fluid. 7

Recommended Aspirin Regimen

• Dosing: Aspirin 150 mg daily is the most commonly studied dose in TBM trials, though doses ranging from 81 mg to 1000 mg daily have been evaluated. 6, 7

• Duration: Continue aspirin for at least 60 days (the duration studied in clinical trials), though longer therapy may be warranted based on stroke risk. 7

• Timing: Initiate aspirin as soon as TBM diagnosis is established, concurrent with anti-tuberculosis therapy and corticosteroids. 6

Critical Adjunctive Therapy

All TBM patients must receive adjunctive corticosteroids regardless of aspirin use, as dexamethasone reduces mortality by approximately 25% (moderate-certainty evidence). 1, 2

• Adult dosing: Dexamethasone 12 mg IV daily for 3 weeks, then taper over 3 weeks (total 6 weeks). 1

• Alternative: Prednisolone 60 mg oral daily, tapered over 6-8 weeks. 1, 2

Contraindications to Aspirin in TBM

Aspirin should be temporarily withheld or delayed in specific circumstances:

• Higher-grade hemorrhagic transformation (HI2, PH1, PH2 on Heidelberg Classification): Delay aspirin for 7-10 days after hemorrhagic transformation is documented. 8

• Active gastrointestinal bleeding: In the randomized trial, GI or cerebral bleeding occurred in 13.9% of placebo patients vs 20-22.9% of aspirin-treated patients (not statistically significant, p=0.59). 7

• Planned craniectomy: If surgical decompression is anticipated, avoid antiplatelet agents until after the procedure. 4

Why Not Enoxaparin?

Therapeutic anticoagulation is contraindicated in acute ischemic stroke and TBM-related infarcts for several reasons:

• No proven benefit: Anticoagulation has not been shown to reduce stroke progression or improve outcomes in non-cardioembolic ischemic stroke. 4

• Increased bleeding risk: Full-dose anticoagulation increases major bleeding 6.0- to 7.7-fold compared to antiplatelet therapy. 4

• Wrong mechanism: TBM infarcts result from inflammatory arteritis with vessel wall infiltration by exudates, not from intraluminal thromboembolism that would respond to anticoagulation. 3

• Guideline recommendations: Stroke guidelines explicitly state that anticoagulation is not recommended for acute ischemic stroke unless there is a specific indication such as atrial fibrillation. 4

Prophylactic Anticoagulation for VTE Prevention

Low-dose prophylactic anticoagulation (not therapeutic) is appropriate for VTE prevention:

• Subcutaneous low-molecular-weight heparin or heparinoids in prophylactic doses should be used for thromboembolic prophylaxis in immobilized TBM patients. 4

• This is distinct from therapeutic anticoagulation and does not contraindicate concurrent aspirin use. 4

Common Pitfalls to Avoid

• Do not use therapeutic anticoagulation (enoxaparin, unfractionated heparin at therapeutic doses, or DOACs) for TBM-related infarcts—there is no evidence of benefit and substantial bleeding risk. 4

• Do not delay aspirin waiting for infarct confirmation on imaging if TBM is diagnosed; early initiation may prevent new infarcts. 7, 5

• Do not omit corticosteroids—they are the only adjunctive therapy with proven mortality benefit and must be given with aspirin. 1, 2

• Do not continue aspirin if higher-grade hemorrhagic transformation develops—switch to observation and repeat imaging before restarting. 8